BC Extra | Mar 1, 2019
Company News

Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc....
BC Week In Review | Nov 30, 2018
Company News

Ascletis adds HBV therapy to portfolio through Roche partnership

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Nov. 20 with exclusive rights to marketed HBV drug Pegasys...
BC Extra | Nov 20, 2018
Company News

Ascletis adds marketed HBV drug from Roche to Chinese portfolio

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Tuesday with exclusive rights to marketed HBV drug Pegasys peginterferon...
BC Week In Review | Dec 1, 2017
Clinical News

CHMP recommends pediatric label expansion for Roche's Pegasys

In October, EMA's CHMP recommended expanding the label of Pegasys peginterferon alfa-2a (RG442) from Roche (SIX:ROG; OTCQX:RHHBY) to treat hepatitis B envelope antigen (HBeAg)-positive chronic HBV infection in non-cirrhotic children and adolescents three years of...
BC Week In Review | Oct 27, 2017
Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat non-cirrhotic, hepatitis B e antigen (HBeAg)-negative, chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir...
BC Extra | Oct 23, 2017
Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir disoproxil fumarate and Pegasys peginterferon alfa-2a...
BC Innovations | Jun 14, 2017
Distillery Therapeutics

Neurology

INDICATION: Depression Analysis of a patient adverse event database and mouse studies suggest promoting the expression of HspH1 could help treat depression. In the FDA Adverse Event Reporting System (FAERS) database, the incidence of depression...
BC Week In Review | Feb 3, 2017
Clinical News

REP 2165-Mg: Preliminary Ph II REP 401 data

Preliminary data from 40 treatment-naïve, non-cirrhotic patients with HBeAg-negative chronic HBV infection in the open-label Phase II REP 401 trial showed that once-weekly 250 mg IV REP 2139-Mg and REP 2165-Mg plus Viread tenofovir and...
BC Week In Review | Feb 3, 2017
Clinical News

REP 2139-Mg: Preliminary Ph II REP 401 data

Preliminary data from 40 treatment-naïve, non-cirrhotic patients with HBeAg-negative chronic HBV infection in the open-label Phase II REP 401 trial showed that once-weekly 250 mg IV REP 2139-Mg and REP 2165-Mg plus Viread tenofovir and...
BC Week In Review | Feb 1, 2016
Clinical News

ARC-520: Phase IIb started

Arrowhead began the open-label, Australian and New Zealand Phase IIb MONARCH (Heparc-2008) trial to evaluate 2 mg/kg IV ARC-520 every 4 weeks for 48 weeks alone or with entecavir and Pegasys peginterferon alfa-2a in up...
Items per page:
1 - 10 of 651